Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-231A
- Development stage
- Phase 1
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-231A is an investigational drug candidate being developed by Addpharma Inc., a South Korean pharmaceutical company specializing in value-added medicines. It is intended for the treatment of hypertension and hyperlipidemia, often as part of a fixed-dose combination strategy. In clinical development, AD-231A has been evaluated in Phase 1 pharmacokinetic interaction studies alongside AD-231B and AD-231C to assess the safety and drug-drug interaction profiles of a potential triple combination therapy. While the specific chemical identity of AD-231A is not publicly disclosed in standard trial registries, it typically represents a standard-of-care agent for cardiovascular management, such as an Angiotensin II Receptor Blocker (ARB), a Calcium Channel Blocker (CCB), or an HMG-CoA reductase inhibitor (statin).
- Other names
- amlodipine camsylate + losartan potassium + rosuvastatin calcium
02
Targets
LTCC (Voltage-gated calcium channel (L-type))HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on AD-231A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-231A.